Literature DB >> 20598056

Erythematous and bullous rash strongly indicating toxic epidermal necrolysis associated with the use of intravenous ritodrine hydrochloride.

Masahiro Shiba1, Koichiro Kido, Koichi Umezawa, Hiroshi Higaki, Sachiyo Matsumoto, Akinori Taguchi, Takashi Hayashi, Yuko Higaki, Yukifumi Sasamori, Norio Shinozuka, Yoji Fuse, Akihiko Kikuchi, Takuya Ayabe.   

Abstract

Toxic epidermal necrolysis (TEN) is a very rare drug reaction associated with a high mortality rate. This condition warrants prompt recognition, diagnosis and treatment. Only one case report of TEN that was possibly induced by ritodrine hydrochloride, a tocolytic agent, was found in English literature. Here, we report the case of a 26-year-old pregnant woman who was suspected with TEN following the intravenous administration of ritodrine hydrochloride in the 35(th) week of gestation. An emergency cesarean section was performed because the labor pains caused systemic intolerable haphalgesia. After the surgery, intensive dermatological treatment commenced, which helped her recover from the serious condition. The result of the drug-induced lymphocyte stimulation test for ritodrine hydrochloride was positive. When a skin eruption appears during the administration of ritodrine, we must consider the benefits as well as the risks of continuous use of tocolytic agents because there is a risk of Stevens-Johnson syndrome or TEN.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598056     DOI: 10.1111/j.1447-0756.2010.01173.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  2 in total

Review 1.  Stevens-Johnson syndrome and toxic epidermal necrolysis in pregnant patients: A systematic review.

Authors:  Ajay N Sharma; Bobak Hedayati; Natasha A Mesinkovska; Scott Worswick
Journal:  Int J Womens Dermatol       Date:  2020-04-13

2.  Toxic epidermal necrolysis induced by ritodrine in pregnancy: A case report.

Authors:  Wen-Yu Liu; Jia-Rong Zhang; Xian-Ming Xu; Tian-Yi Ye
Journal:  World J Clin Cases       Date:  2022-02-06       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.